SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit is drawing attention for clinical progress with ivonescimab, including reported Phase III survival benefits versus established cancer therapies and upcoming regulatory and trial milestones. Bullish traders see the results as evidence of broader potential, while skeptics emphasize unresolved FDA approval risk, questions about how China-based data translate, and concerns about possible dilution.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas selection for the U.S. Armys ALATTIS program to develop 10 kV silicon-carbide technology is drawing attention as a government validation of its technology and a potential longer-term defense opportunity. Traders are bullish on the recognition but note that the awards financial terms were not disclosed, so its near-term revenue impact is uncertain; discussion also centers on short interest and the stocks volatile reaction.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing shares are under pressure after the FAA delayed 737 MAX 10 certification while reviewing a flight-management software glitch that can disrupt automated guidance in a specific missed-approach scenario. Traders disagree on whether the issue is a manageable, previously disclosed fix or another sign of quality and execution problems, with the certification delay adding uncertainty.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Kodiaks shares surged after Phase 3 DAYBREAK results showed Zenkuda and tabirafusp-ted met key goals in wet AMD, with vision outcomes comparable to Eylea and Zenkuda showing potential for longer dosing intervals; the company plans an FDA filing for Zenkuda. Traders celebrated the results and possible short covering, while others warned the rally may be overextended and debated future financing and dilution risks.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit shares are under pressure amid concern that Googles publisher-payment pilot could reduce the likelihood of a favorable renewal of its AI data-licensing deal with Reddit. Traders also blame persistent insider selling and weak price action, while some view the pullback as a buying opportunity; others say there is no clear new company-specific catalyst.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

HBARs sharp rally and surge in volume are being linked by traders to enterprise-AI developments, including IBM-related integration and Hedera ecosystem participation in NVIDIAs Open Agent Safety Platform. The reaction is largely bullish, with talk of a breakout and short squeeze, though some traders question the catalyst and warn of profit-taking or a pullback.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

Starships first orbital flight and deployment of 26 next-generation Starlink satellites dominate discussion, with bulls viewing the mission as a step toward expanding Starlink capacity and commercial use of Starship. Traders disagree on the significance: some call it a major milestone, while others focus on engine trouble, the shortened mission and splashdown, alongside a muted or negative stock reaction.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is drawing attention over a proposed Iowa steel plant backed by Mesabi Metallics, which traders worry could add future competition; many doubt the project will be financed or completed, while others view the selloff as overdone because construction would take years. Hamilton production cuts and layoffs are also fueling near-term concern about CLFs operations.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZeneca shares have been reacting to positive late-stage clinical trial results for its COPD drug, tozorakimab, which met primary endpoints and revived confidence in the company's respiratory pipeline.

Spdr Dow Jones Industrial Average ETF Trust - Spdr Dow Jones Industrial Average ETF Trust

Rising Treasury yields and oil-driven inflation concerns are weighing on the Dow and reinforcing fears of further Fed tightening. Traders are split between expecting more downside and viewing the pullback as a buying opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

UBS tells clients to consider Asia and Europe as stocks hit new highs

Investing.com -- UBS said in a note Tuesday that investors should broaden their exposure to international equities as U.S. markets continue their upward streak and valuations begin to look stretched.

Earnings replacing tariffs as the primary focus for investors: Barclays

Investing.com -- Investor attention is shifting from geopolitics to corporate fundamentals as earnings begin to eclipse tariffs as the primary market catalyst, according to Barclays.

EU stocks poised for breakout as tariff fears ease: Barclays

Investing.com -- Easing tariff concerns could fuel a breakout in European equities after months of market stagnation, according to Barclays analysts. 

BofA on European earnings: Upside surprise to low expectations

Investing.com -- Second-quarter earnings for European companies have come in ahead of expectations, with financials and U.S.-exposed sectors leading the surprise, Bank of America (BofA) analysts said.

European stocks muted as traders assess earnings, crunch trade talks

Investing.com - European stocks were subdued on Monday, as investors assess a range of corporate earnings and ongoing trade negotiations between the U.S. and the European Union.

Barclays warns: ’Negative summer seasonality’ is looming

Investing.com -- Barclays is warning that markets face “negative summer seasonality,” as August and September typically bring elevated volatility, with policy uncertainty and rising rates adding to investor unease.

Could renewed US fiscal stimulus shield markets from rising tariff risk?

Investing.com -- The potential for near-term U.S. fiscal support may help cushion markets against escalating trade tensions, according to analysts at Bank of America.

BofA survey: Investors more bullish on EU equities, U.S. growth expected to slow

Investing.com -- European fund managers have grown more optimistic about the region’s growth and equities outlook, with a clear tilt away from the U.S. as confidence in its economic momentum wanes, according to Bank of America Securities’ latest monthly survey.

Jefferies downgrades Hermès to “hold” on FX impact, slower growth

STOXX Europe 600: UBS weighs in as index hits its 2025 price target

Investing.com -- The STOXX 600 index has reached UBS’s 2025 price target of 550, prompting the bank to weigh in on the outlook for the region’s equities. UBS strategists reiterated a neutral stance on the index at current levels, but see potential for upside into 2026.

Neutral Sentiment

Adding risk (buying more)

Trimming/taking profits

Rotating into safer assets

Staying the course, no changes

We&#39;re about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Stocktwits

We're about to enter Q4 - how are you positioning your portfolio for the rest of the year?

STOXX EURO STOXX 50